Oblimersen and α-interferon in metastatic renal cancer: A phase II study of the California Cancer Consortium

Journal of Cancer Research and Clinical Oncology

Volumn 133, Issue 10, 2007, Pages 705-711

  Margolin, Kim ^a   Synold, Timothy W ^a   Lara, Primo ^b   Frankel, Paul ^c   Lacey, Simon F ^d   Quinn, David I ^e   Baratta, Tracey ^c   Dutcher, Janice P ^f   Xi, Bixin ^a   Diamond, Don J ^d   Gandara, David R ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Division of Information Sciences   (United States)

^d City of Hope   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f OUR LADY OF MERCY MEDICAL CENTER   (United States)

Author keywords

Interferon; G3139; Oblimersen; Phase II; Renal cancer

Indexed keywords

ALPHA INTERFERON; ANNEXIN; CD3 ANTIGEN; INTERLEUKIN 2; OBLIMERSEN; PROTEIN BCL 2;

ADULT; AGED; ANAMNESIS; APOPTOSIS; ARTICLE; BLOOD ANALYSIS; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MEGADOSE; FATIGUE; FEMALE; FEVER; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY CANCER; LABORATORY TEST; LYMPHOCYTE; LYMPHOCYTOPENIA; MALE; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STEADY STATE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; THIONUCLEOTIDES;

EID: 34548265236     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-007-0200-6     Document Type: Article

References (33)

1. Adams JM, Cory S (1998) The Bcl-2 protein family: arbiters of cell survival. Science 281:1322-1326
2. 6-alkylguanine-DNA alkyltransferase. Mol Cancer Ther 3:1215-1220
3. Bhargava V, Kell DL, van de Rijn M, Warnke RA (1994) Bc1-2 Immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 145:535-540
4. Chandler D, el-Naggar AK, Brisbay S et al (1994) Apoptosis and expression of the bcl-2 proto-oncogene in the fetal and adult human kidney: evidence for the contribution of bcl-2 expression to renal carcinogenesis. Hum Pathol 25:789-796
5. Colombel M, Symmans F, Gil S et al (1993) Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143:390-4009
6. Dai G, Wei X, Liu Z et al (2005) Characterization and quantification of Bcl-2 antisense oblimersen and metabolites in plasma and urine by ion-pair reversed phase HPLC coupled with electrospray ion-trap mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 825:201-213
7. Demir G, Ozguroglu M, Sayhan N et al (1999) Immunomodulating therapy with rIL-2 and interferon alpha-induces in vivo expression of bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (a pilot study). Anticancer Res 19:3517-3520
8. Devarajan P, De Leon M, Talasazan F et al (2001) The von Hippel-Lindau gene product inhibits renal cell apoptosis via bcl-2-dependent pathways. J Biol Chem 276:40599-40605
9. Fosså SD (2000) Interferon in metastatic renal cell carcinoma. Semin Oncol 27:187-193
10. McDonnell TJ, Korsmeyer SJ (1991) Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the †(14;18). Nature 349:254-256
11. Gaulard P, d'Agay MF, Peuchmaur M et al (1992) Expression of the bcl-2 gene product in follicular lymphoma. Am J Pathol 140:1089-1095
12. Hara I, Hara S, Miyake H et al (2001) Bcl-2 modulates Fas-mediated apoptosis in human renal cell carcinoma cell lines. Int J Oncol 18:1181-1185
13. Henry SP, Monteith D, Levin AA (1997) Antisense oligonucleotide inhibitors for the treatment of cancer. 2. Toxicological properties of phosphorothioate oligonucleotides. Anti-Cancer Drug Des 12:395-408
14. Ikegaki N, Katsumata M et al (1994) Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 54:6-8
15. Jiang SX, Yuichi S et al (1995) Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 177:135-138
16. Leek RD, Kaklamanis L et al (1994) Bcl-2 in normal human breast and carcinoma, association with estrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 69:135-139
17. Lu QL, Elia G et al (1993) Bcl-2 Proto-oncogene expression in Epstein-Barr-Virus associated nasopharyngeal carcinoma. Int J Cancer 53:29-35
18. Marcucci G, Byrd JC, Dai G et al (2003) Phase 1 and pharmacodynamic studies of oblimersen, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 101:425-432
19. Marcucci G, Stock W, Dai G et al (2005) Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol 23:3404-3411
20. Margolin KA (2000) Interleukin-2 in the treatment of renal cancer. Semin Oncol 27:194-203
21. TM, oblimersen) and irinotecan in patients with metastatic colorectal cancer. Ann Oncol 17:313-321
22. O'Brien SM, Cunningham CC, Golenkov AK et al (2005) Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 23:7697-7702
23. O'Donnell TJ, Troncoso P et al (1992) Expression of the protooncogene bcl2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944
24. Paraf F, Chauveau D, Chretien Y et al (2000) Renal lesions in von Hippel-Lindau disease: immunohistochemical expression of nephron differentiation molecules, adhesion molecules and apoptosis proteins. Histopathology 36:457-465
25. Rudin CM, Kozloff M, Hoffman PC et al (2004) Phase I Study oblimersen, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 22:1110-1117
26. Semino C, Ferlazzo G, Pietra G et al (1992) Heterogeneity of the alpha-interferon-mediated-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J Clin Oncol 10:735-746
27. Silvestrini R, Veneroni S, Daidone MG et al (1994) The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Canc Inst 86:499-504
28. Sinicrope FA, Ruan SB et al (1995) Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 55:237-241
29. Stein CA, Benimetskaya L, Mani S (2005) Antisense strategies for oncogene inactivation. Semin Oncol 32:563-572
30. Therasse P, Arbuck S, Eisenhauer E, Wanders J et al (2006) New guidelines to evaluate the response to treatment in solid tumors. JNCI 92:205-216
31. Tolcher AW, Kuhn J, Schwartz G et al (2004) A phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, Oblimersen), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 10:5048-5057
32. Tolcher AW, Kim C, Kuhn J et al (2005) A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 11:3854-3861
33. Waters JS, Webb A, Cunningham D et al (2000) Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 18:1812-1823